secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001816590-24-000083
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint
--------------------------------------------------------------------------------

- Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.
- No serious adverse events; common AEs mild: headache (50%), nausea (36.4%), crying (27.3%), fatigue (27.3%).
- Mean CAPS-5 total score reduced 29.9 points at week 4 and 29.5 points at week 12 from baseline of 47.5.
- Response rate (≥15-point CAPS-5 improvement) 81.8% at week 4 and 77.3% at week 12; remission rate 63.6% at week 4.
- No patient withdrawals and no return to antidepressant medication during the 12-week study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/0001816590-24-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/cmps-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001816590-24-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer